idarubicin has been researched along with Down Syndrome in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bochennek, K; Creutzig, U; Gilfert, J; Hassler, A; Lehrnbecher, T; Perner, C; Reinhardt, D; Schöning, S | 1 |
| Creutzig, U; Diekamp, S; Dworzak, M; Reinhardt, D; Stary, J; Zimmermann, M | 1 |
| Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Tzeng, CH; Wei, CH; Yu, IT | 1 |
| Alfaro, E; Casak, S; Cygler, A; Felice, MS; Fraquelli, L; Gallego, M; Pérez, LE; Quinteros, R; Sackmann-Muriel, F; Zubizarreta, P | 1 |
2 trial(s) available for idarubicin and Down Syndrome
| Article | Year |
|---|---|
Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Infections; Leukemia, Myeloid, Acute; Male; Mitoxantrone | 2016 |
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Survival Rate; Treatment Outcome | 2005 |
2 other study(ies) available for idarubicin and Down Syndrome
| Article | Year |
|---|---|
Trisomy 21 in acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Down Syndrome; Humans; Hydroxyurea; Idarubicin; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Acute; Male; Mitoxantrone | 1996 |
Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Argentina; Bone Marrow Cells; Child, Preschool; Cytarabine; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Karyotyping; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Treatment Outcome | 1998 |